Moving in the right direction. Looking at the annual result when you take out the non-recurring legal fees and staff costs (I won't excuse these but at least they are now in the past) the net position was a loss of $5m. Cost control is improving. The growing arr per customer is pleasing and a continued focus on the larger enterprise customers will only help overhead costs where otherwise unnecessary energy goes to small paying clients. Good signs for FY22. Keen to see what the annual report brings around the strategic business review - "company strategy and vision going forward".
- Forums
- ASX - By Stock
- LVT
- Ann: FY21 Q4 Quarterly Activities Report and Appendix 4C
Ann: FY21 Q4 Quarterly Activities Report and Appendix 4C, page-6
Featured News
Add LVT (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online